Press Release
| January 5, 2010
Firm Represents Merz Pharma in Acquisition of BioForm Medical
(New York, January 5, 2010) — A team of lawyers from four offices has advised Merz Pharma Group, a privately held company from Frankfurt, Germany with revenue in excess of US $800 million, in its US $253 million agreement to acquire all outstanding shares of BioForm Medical group in a cash tender offer followed by a second-step merger. BioForm is a medical aesthetics company headquartered in San Mateo, California, that develops products that enhance aesthetic procedures performed in dermatology and plastic surgery practices.
The US $5.45 per share cash purchase price represents a premium of 55 percent over BioForm Medical's 30-day average closing stock price, and a premium of 60 percent over the closing price of BioForm Medical's common stock on December 31, 2009, the last trading day prior to the announcement.
The firm's deal team, which spanned the Silicon Valley, New York, Washington, DC and Frankfurt offices, was led by Partners Keith Flaum and Lorenzo Borgogni. Assistance was provided by Partners Stanton J. Lovenworth, Howard Adler, John F. Collins, Robert G. Lorndale and Joe Marx, Counsel Kenneth Barr and Associates Jon D. Kukulski, Dan C. Hackney, Aaron Belcher, Nathan C. Dee, Rosa K. Walker, Nathan D. Bentley and Sean C. McKeever.
This memorandum is intended only as a general discussion of these issues. It is not considered to be legal advice. We would be pleased to provide additional details or advice about specific situations. For additional information on this important topic, please feel free to call upon your Dewey & LeBoeuf relationship partner. No part of this publication may be reproduced, in whole or in part, in any form, without our prior written consent.
For further information on Dewey & LeBoeuf, please visit www.dl.com. +1 888 532 6383